Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BotVax B is a USDA-approved monovalent toxoid vaccine used for the prevention of equine botulism caused by Clostridium botulinum Type B in healthy horses. It contains purified, inactivated (toxoid) form of the type B toxin adsorbed onto aluminum phosphate and preserved with thimerosal. The vaccine stimulates an immune response without causing disease, providing active immunity to vaccinated horses and passive immunity to foals via immunized pregnant mares. It is safe for use in adult horses, pregnant mares, and foals as young as two weeks old. Botulism Type B accounts for over 85% of equine cases and can be rapidly fatal; vaccination is considered critical preventive care according to AAEP guidelines[1][2][3][4][5][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BotVax B.